{
  "success": true,
  "pagesUsed": [
    3,
    8,
    16,
    20
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "Title Page",
        "text": "Title Page",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.0",
        "sectionTitle": "Title Page",
        "sectionType": {
          "id": "b62c7d51-5476-4abd-a05a-7a66dad66e67",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "Protocol Amendment: Summary of Changes",
        "text": "Protocol Amendment: Summary of Changes",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.1",
        "sectionTitle": "Protocol Amendment: Summary of Changes",
        "sectionType": {
          "id": "5c98e2b0-10c8-4e99-9913-ed17a893c0d3",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "Synopsis",
        "text": "Synopsis",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.2",
        "sectionTitle": "Synopsis",
        "sectionType": {
          "id": "6016375f-becc-4c78-9f9a-2fe44d425a23",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "List of Abbreviations and Definition of Terms",
        "text": "List of Abbreviations and Definition of Terms",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.3",
        "sectionTitle": "List of Abbreviations and Definition of Terms",
        "sectionType": {
          "id": "837641a7-b802-4659-b60d-a81278125d23",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_5",
        "name": "Table of Contents",
        "text": "Table of Contents",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2.0",
        "sectionTitle": "Table of Contents",
        "sectionType": {
          "id": "be0c1246-1ac7-4a0d-828d-d7e62dbab9b7",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_6",
        "name": "Introduction",
        "text": "Introduction",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3.0",
        "sectionTitle": "Introduction",
        "sectionType": {
          "id": "94668304-02a1-455b-b10a-0a7176ef5158",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2"
        ]
      },
      {
        "id": "nc_7",
        "name": "Study Objectives",
        "text": "Study Objectives",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4.0",
        "sectionTitle": "Study Objectives",
        "sectionType": {
          "id": "4af83279-896c-47e0-9018-1b74074ee8b2",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_8",
        "name": "Investigational Plan",
        "text": "Investigational Plan",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5.0",
        "sectionTitle": "Investigational Plan",
        "sectionType": {
          "id": "f8fbac6e-3b79-44ef-9fec-870115066e8b",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_8_1",
          "nci_8_2",
          "nci_8_3",
          "nci_8_4",
          "nci_8_5",
          "nci_8_6",
          "nci_8_7",
          "nci_8_8",
          "nci_8_9",
          "nci_8_10",
          "nci_8_11",
          "nci_8_12",
          "nci_8_13",
          "nci_8_14",
          "nci_8_15",
          "nci_8_16",
          "nci_8_17",
          "nci_8_18"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_6_1",
        "name": "Differences Statement",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Differences Statement"
      },
      {
        "id": "nci_6_2",
        "name": "Benefits and Risks",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Benefits and Risks"
      },
      {
        "id": "nci_8_1",
        "name": "Overall Study Design and Plan: Description",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.1",
        "sectionTitle": "Overall Study Design and Plan: Description"
      },
      {
        "id": "nci_8_2",
        "name": "Selection of Study Population",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2",
        "sectionTitle": "Selection of Study Population"
      },
      {
        "id": "nci_8_3",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_8_4",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_8_5",
        "name": "Prior and Concomitant Therapy",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3",
        "sectionTitle": "Prior and Concomitant Therapy"
      },
      {
        "id": "nci_8_6",
        "name": "Permitted Background RA Therapy",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3.1",
        "sectionTitle": "Permitted Background RA Therapy"
      },
      {
        "id": "nci_8_7",
        "name": "Prohibited Therapy",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3.2",
        "sectionTitle": "Prohibited Therapy"
      },
      {
        "id": "nci_8_8",
        "name": "Contraception Recommendations",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.4",
        "sectionTitle": "Contraception Recommendations"
      },
      {
        "id": "nci_8_9",
        "name": "Efficacy, Pharmacokinetic, Pharmacodynamic, Exploratory Research and Validation Studies, and Safety Assessments/Variables",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3",
        "sectionTitle": "Efficacy, Pharmacokinetic, Pharmacodynamic, Exploratory Research and Validation Studies, and Safety Assessments/Variables"
      },
      {
        "id": "nci_8_10",
        "name": "Efficacy and Safety Measurements Assessed and Flow Chart",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.1",
        "sectionTitle": "Efficacy and Safety Measurements Assessed and Flow Chart"
      },
      {
        "id": "nci_8_11",
        "name": "Study Procedures",
        "text": "",
        "order": 10,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.1.1",
        "sectionTitle": "Study Procedures"
      },
      {
        "id": "nci_8_12",
        "name": "Collection and Handling of Optional samples for Exploratory Research and Validation Studies",
        "text": "",
        "order": 11,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.1.2",
        "sectionTitle": "Collection and Handling of Optional samples for Exploratory Research and Validation Studies"
      },
      {
        "id": "nci_8_13",
        "name": "Drug Concentration Measurements",
        "text": "",
        "order": 12,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.2",
        "sectionTitle": "Drug Concentration Measurements"
      },
      {
        "id": "nci_8_14",
        "name": "Collection of Samples for Analysis",
        "text": "",
        "order": 13,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.2.1",
        "sectionTitle": "Collection of Samples for Analysis"
      },
      {
        "id": "nci_8_15",
        "name": "Measurement Methods",
        "text": "",
        "order": 14,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.2.2",
        "sectionTitle": "Measurement Methods"
      },
      {
        "id": "nci_8_16",
        "name": "Efficacy Variables",
        "text": "",
        "order": 15,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3",
        "sectionTitle": "Efficacy Variables"
      },
      {
        "id": "nci_8_17",
        "name": "Period 1 Variables",
        "text": "",
        "order": 16,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3.1",
        "sectionTitle": "Period 1 Variables"
      },
      {
        "id": "nci_8_18",
        "name": "Primary Variable",
        "text": "",
        "order": 17,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3.1.1",
        "sectionTitle": "Primary Variable"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "DTP",
        "expandedText": "Direct-to Patient",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "COVID-19",
        "expandedText": "Coronavirus Disease – 19",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "IRB",
        "expandedText": "Institutional Review Board",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "IEC",
        "expandedText": "Independent Ethics Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "MTX",
        "expandedText": "Methotrexate",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "QD",
        "expandedText": "once daily",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "MTX-IR",
        "expandedText": "MTX-inadequate response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "RA",
        "expandedText": "rheumatoid arthritis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "ACR",
        "expandedText": "American College of Rheumatology",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "EULAR",
        "expandedText": "European League Against Rheumatism",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "hsCRP",
        "expandedText": "high-sensitivity C-reactive protein",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "AE",
        "expandedText": "adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "ALC",
        "expandedText": "absolute lymphocyte count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "ALT",
        "expandedText": "alanine transaminase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "ANC",
        "expandedText": "absolute neutrophil count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "AST",
        "expandedText": "aspartate transaminase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "BCG",
        "expandedText": "Bacille Calmette-Guérin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "bDMARDs",
        "expandedText": "biologic disease-modifying anti-rheumatic drug",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "BUN",
        "expandedText": "blood urea nitrogen",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "CBC",
        "expandedText": "complete blood count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "CCP",
        "expandedText": "cyclic citrullinated peptide",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "CDAI",
        "expandedText": "clinical disease activity index",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "CGC",
        "expandedText": "common gamma-chain",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "CL/F",
        "expandedText": "apparent clearance",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "CPK",
        "expandedText": "creatine phosphokinase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "CR",
        "expandedText": "clinical remission",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "CRF",
        "expandedText": "case report form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "CRP",
        "expandedText": "c-reactive protein",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "csDMARD",
        "expandedText": "conventional synthetic disease-modifying anti-rheumatic drug",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "CSR",
        "expandedText": "clinical study report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "CXR",
        "expandedText": "chest x-ray",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "CYP3A",
        "expandedText": "Cytochrome P450 3A",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "DAS",
        "expandedText": "disease activity score",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_34",
        "abbreviatedText": "DMARD",
        "expandedText": "disease-modifying anti-rheumatic drug",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_35",
        "abbreviatedText": "DMC",
        "expandedText": "Data Monitoring Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_36",
        "abbreviatedText": "DNA",
        "expandedText": "Deoxyribonucleic acid",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_37",
        "abbreviatedText": "ECG",
        "expandedText": "electrocardiogram",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_38",
        "abbreviatedText": "eCRF",
        "expandedText": "electronic case report form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_39",
        "abbreviatedText": "EDC",
        "expandedText": "electronic data capture",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 8,
      "itemCount": 20,
      "abbreviationCount": 39
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment 7",
      "versionDate": "04 December 2020",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "DTP",
          "expansion": "Direct-to Patient"
        },
        {
          "abbreviation": "COVID-19",
          "expansion": "Coronavirus Disease – 19"
        },
        {
          "abbreviation": "IRB",
          "expansion": "Institutional Review Board"
        },
        {
          "abbreviation": "IEC",
          "expansion": "Independent Ethics Committee"
        },
        {
          "abbreviation": "MTX",
          "expansion": "Methotrexate"
        },
        {
          "abbreviation": "QD",
          "expansion": "once daily"
        },
        {
          "abbreviation": "MTX-IR",
          "expansion": "MTX-inadequate response"
        },
        {
          "abbreviation": "RA",
          "expansion": "rheumatoid arthritis"
        },
        {
          "abbreviation": "ACR",
          "expansion": "American College of Rheumatology"
        },
        {
          "abbreviation": "EULAR",
          "expansion": "European League Against Rheumatism"
        },
        {
          "abbreviation": "hsCRP",
          "expansion": "high-sensitivity C-reactive protein"
        },
        {
          "abbreviation": "AE",
          "expansion": "adverse event"
        },
        {
          "abbreviation": "ALC",
          "expansion": "absolute lymphocyte count"
        },
        {
          "abbreviation": "ALT",
          "expansion": "alanine transaminase"
        },
        {
          "abbreviation": "ANC",
          "expansion": "absolute neutrophil count"
        },
        {
          "abbreviation": "AST",
          "expansion": "aspartate transaminase"
        },
        {
          "abbreviation": "BCG",
          "expansion": "Bacille Calmette-Guérin"
        },
        {
          "abbreviation": "bDMARDs",
          "expansion": "biologic disease-modifying anti-rheumatic drug"
        },
        {
          "abbreviation": "BUN",
          "expansion": "blood urea nitrogen"
        },
        {
          "abbreviation": "CBC",
          "expansion": "complete blood count"
        },
        {
          "abbreviation": "CCP",
          "expansion": "cyclic citrullinated peptide"
        },
        {
          "abbreviation": "CDAI",
          "expansion": "clinical disease activity index"
        },
        {
          "abbreviation": "CGC",
          "expansion": "common gamma-chain"
        },
        {
          "abbreviation": "CL/F",
          "expansion": "apparent clearance"
        },
        {
          "abbreviation": "CPK",
          "expansion": "creatine phosphokinase"
        },
        {
          "abbreviation": "CR",
          "expansion": "clinical remission"
        },
        {
          "abbreviation": "CRF",
          "expansion": "case report form"
        },
        {
          "abbreviation": "CRP",
          "expansion": "c-reactive protein"
        },
        {
          "abbreviation": "csDMARD",
          "expansion": "conventional synthetic disease-modifying anti-rheumatic drug"
        },
        {
          "abbreviation": "CSR",
          "expansion": "clinical study report"
        },
        {
          "abbreviation": "CXR",
          "expansion": "chest x-ray"
        },
        {
          "abbreviation": "CYP3A",
          "expansion": "Cytochrome P450 3A"
        },
        {
          "abbreviation": "DAS",
          "expansion": "disease activity score"
        },
        {
          "abbreviation": "DMARD",
          "expansion": "disease-modifying anti-rheumatic drug"
        },
        {
          "abbreviation": "DMC",
          "expansion": "Data Monitoring Committee"
        },
        {
          "abbreviation": "DNA",
          "expansion": "Deoxyribonucleic acid"
        },
        {
          "abbreviation": "ECG",
          "expansion": "electrocardiogram"
        },
        {
          "abbreviation": "eCRF",
          "expansion": "electronic case report form"
        },
        {
          "abbreviation": "EDC",
          "expansion": "electronic data capture"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX",
        "version": "Amendment 7",
        "versionDate": "04 December 2020"
      },
      "sections": [
        {
          "number": "1.0",
          "title": "Title Page",
          "type": "Other"
        },
        {
          "number": "1.1",
          "title": "Protocol Amendment: Summary of Changes",
          "type": "Other"
        },
        {
          "number": "1.2",
          "title": "Synopsis",
          "type": "Synopsis"
        },
        {
          "number": "1.3",
          "title": "List of Abbreviations and Definition of Terms",
          "type": "Other"
        },
        {
          "number": "2.0",
          "title": "Table of Contents",
          "type": "Other"
        },
        {
          "number": "3.0",
          "title": "Introduction",
          "type": "Introduction",
          "subsections": [
            {
              "number": "3.1",
              "title": "Differences Statement"
            },
            {
              "number": "3.2",
              "title": "Benefits and Risks"
            }
          ]
        },
        {
          "number": "4.0",
          "title": "Study Objectives",
          "type": "Objectives"
        },
        {
          "number": "5.0",
          "title": "Investigational Plan",
          "type": "Study Design",
          "subsections": [
            {
              "number": "5.1",
              "title": "Overall Study Design and Plan: Description"
            },
            {
              "number": "5.2",
              "title": "Selection of Study Population"
            },
            {
              "number": "5.2.1",
              "title": "Inclusion Criteria"
            },
            {
              "number": "5.2.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "5.2.3",
              "title": "Prior and Concomitant Therapy"
            },
            {
              "number": "5.2.3.1",
              "title": "Permitted Background RA Therapy"
            },
            {
              "number": "5.2.3.2",
              "title": "Prohibited Therapy"
            },
            {
              "number": "5.2.4",
              "title": "Contraception Recommendations"
            },
            {
              "number": "5.3",
              "title": "Efficacy, Pharmacokinetic, Pharmacodynamic, Exploratory Research and Validation Studies, and Safety Assessments/Variables"
            },
            {
              "number": "5.3.1",
              "title": "Efficacy and Safety Measurements Assessed and Flow Chart"
            },
            {
              "number": "5.3.1.1",
              "title": "Study Procedures"
            },
            {
              "number": "5.3.1.2",
              "title": "Collection and Handling of Optional samples for Exploratory Research and Validation Studies"
            },
            {
              "number": "5.3.2",
              "title": "Drug Concentration Measurements"
            },
            {
              "number": "5.3.2.1",
              "title": "Collection of Samples for Analysis"
            },
            {
              "number": "5.3.2.2",
              "title": "Measurement Methods"
            },
            {
              "number": "5.3.3",
              "title": "Efficacy Variables"
            },
            {
              "number": "5.3.3.1",
              "title": "Period 1 Variables"
            },
            {
              "number": "5.3.3.1.1",
              "title": "Primary Variable"
            }
          ]
        }
      ]
    }
  }
}